MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Our first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for debridement of deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Utilizing the same proprietary enzymatic technology, EscharEx® is a promising candidate in Phase III for the debridement of chronic wounds, with estimated peak sales of $831M in the United States. Phase II clinical trials showed that EscharEx has distinct advantages over the currently available $370+ million legacy drug, presenting a unique opportunity for significant market growth.

www.mediwound.com & LinkedIn.